^
    Back
    Association details:
    Biomarker:TFE3 fusion
    Cancer:Sarcoma
    Drug:Votrient (pazopanib) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Pazopanib for Metastatic Alveolar Soft Part Sarcoma

    Excerpt:
    ...- Histologically confirmed diagnosis of alveolar soft part sarcoma harboring TFE3 fusion at stage IV or at relapse...
    Trial ID:
    NCT02113826
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    ASCO 2018
    Title:

    The utility of integrative genomic profiling in sarcoma diagnosis and treatment.

    Published date:
    05/16/2018
    Excerpt:
    A sixteen year old patient, who was diagnosed by NGS as alveolar soft part sarcoma featured by TFE3 fusion with primary lesion on left thigh and distal brain metastasis, achieved partial response after three months of pazopanib treatment.